Heron Therapeutics (HRTX) News Today

Heron Therapeutics, Inc. (NASDAQ: HRTX) is receiving mixed signals. The stock has edged higher, but the main fundamental development is a series of downward earnings revisions that underscores continued profitability concerns.

• Positive Sentiment: Heron amended and extended its Tax Benefit Preservation Plan, which is intended to protect the company’s net operating losses and other tax attributes by limiting ownership changes. Preserving these tax assets could reduce future tax liabilities if Heron returns to profitability. Heron Therapeutics Extends Tax Benefit Preservation Plan Timeline
• Neutral Sentiment: HC Wainwright maintained a Neutral rating on HRTX. Its estimates imply a gradual path toward profitability, with projected losses through fiscal 2029 and modest earnings of $0.01 per share in fiscal 2030. Heron Therapeutics Analyst Estimates
• Negative Sentiment: HC Wainwright reduced its fiscal 2026 EPS forecast to a loss of $0.14 from a loss of $0.09 and lowered its third- and fourth-quarter 2026 estimates to losses of $0.03 per share each. The firm also cut projections for fiscal 2028, 2029 and 2030, including reducing fiscal 2030 earnings to $0.01 from $0.32. These revisions signal weaker near- and long-term earnings expectations. HC Wainwright Lowers Heron Therapeutics Earnings Estimates
• Negative Sentiment: The latest reported quarter showed a $0.03-per-share loss and revenue of $37.67 million, below the $42.19 million analyst expectation. With the shares near their 12-month low and below both their 50-day and 200-day moving averages, investors remain focused on cash generation and the company’s ability to improve operating results.